Mesa Laboratories (NASDAQ:MLAB) Posts Earnings Results, Beats Expectations By $0.67 EPS

Key Points

• Mesa Laboratories beat earnings expectations, reporting $2.76 EPS versus the $2.09 consensus estimate, a $0.67 upside. Revenue came in at $63.72 million, slightly below analyst expectations of $65.21 million.
• The company also announced a quarterly dividend of $0.16 per share, payable June 15 to shareholders of record on May 29. That works out to a $0.64 annualized dividend yield of 0.6%, with a payout ratio of 100%.
• Despite the earnings beat, Wall Street remains cautious: the stock carries a consensus “Reduce” rating with an average price target of $94.00. Insider buying and recent institutional additions suggest some confidence in the company’s prospects.

Mesa Laboratories (NASDAQ:MLAB - Get Free Report) posted its quarterly earnings results on Wednesday. The medical instruments supplier reported $2.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.09 by $0.67, FiscalAI reports. The firm had revenue of $63.72 million for the quarter, compared to analyst estimates of $65.21 million. Mesa Laboratories had a net margin of 1.51% and a return on equity of 22.02%.

Mesa Laboratories Stock Performance

NASDAQ MLAB opened at $106.17 on Wednesday. The firm has a 50-day moving average of $95.73 and a 200-day moving average of $87.51. The company has a debt-to-equity ratio of 0.86, a quick ratio of 1.45 and a current ratio of 1.94. The stock has a market cap of $586.06 million, a PE ratio of 165.89 and a beta of 0.94. Mesa Laboratories has a 52-week low of $55.45 and a 52-week high of $115.35.

Mesa Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 15th. Stockholders of record on Friday, May 29th will be given a $0.16 dividend. The ex-dividend date of this dividend is Friday, May 29th. This represents a $0.64 annualized dividend and a dividend yield of 0.6%. Mesa Laboratories's dividend payout ratio is presently 100.00%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on MLAB. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Mesa Laboratories in a report on Monday, May 4th. Wells Fargo & Company lifted their price target on Mesa Laboratories from $83.00 to $94.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 4th. Finally, Wall Street Zen raised Mesa Laboratories from a "buy" rating to a "strong-buy" rating in a research report on Saturday, February 7th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Mesa Laboratories has a consensus rating of "Reduce" and an average price target of $94.00.

Insider Activity at Mesa Laboratories

In related news, Director Shiraz Shabanali Ladiwala purchased 3,500 shares of the firm's stock in a transaction that occurred on Tuesday, March 10th. The shares were acquired at an average price of $72.23 per share, for a total transaction of $252,805.00. Following the purchase, the director owned 8,523 shares in the company, valued at approximately $615,616.29. This represents a 69.68% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Mark Christopher Capone acquired 1,301 shares of the business's stock in a transaction on Tuesday, March 10th. The shares were bought at an average price of $76.35 per share, with a total value of $99,331.35. Following the completion of the transaction, the director directly owned 3,429 shares of the company's stock, valued at approximately $261,804.15. The trade was a 61.14% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have purchased 6,116 shares of company stock worth $452,076. Insiders own 4.90% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Royal Bank of Canada lifted its holdings in shares of Mesa Laboratories by 1.2% during the first quarter. Royal Bank of Canada now owns 30,772 shares of the medical instruments supplier's stock worth $3,652,000 after buying an additional 353 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in Mesa Laboratories during the first quarter worth about $335,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Mesa Laboratories by 4.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,068 shares of the medical instruments supplier's stock worth $364,000 after purchasing an additional 143 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Mesa Laboratories by 3.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 19,977 shares of the medical instruments supplier's stock valued at $2,370,000 after purchasing an additional 685 shares during the period. Finally, American Century Companies Inc. boosted its holdings in Mesa Laboratories by 1.5% in the 2nd quarter. American Century Companies Inc. now owns 13,431 shares of the medical instruments supplier's stock valued at $1,265,000 after purchasing an additional 194 shares during the period. 90.60% of the stock is owned by institutional investors and hedge funds.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc NASDAQ: MLAB is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company's product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.